Latest News
-
Rs 17/Share Dividend: Record Date On April 26; Buy The ICICI Group Stock To Be Eligible? -
Honasa Consumer to Strengthen Operations by Merging Fusion Cosmeceutics and Just4Kids -
Wipro Reports 7.8% Decline in Q4 Net Profit; CEO Highlights Economic Challenges -
IREDA Hits Record Annual PAT of Rs 1,252 Cr in FY24; Q4 Profits Up by 33% -
Massive Employee Exodus Hits India's Top IT Companies in FY23-24 -
Air India Enhances Operational Efficiency with New Crew Management System -
BlackRock Acquires Shares in Electrosteel Castings and PTC India for Rs 207 Crore -
IndiGo Enhances Domestic Routes with Direct Chennai-Durgapur Flights -
Tesla to Recall Nearly 4,000 Cybertrucks Over Accelerator Pedal Fault -
Reliance, ONGC, Tata, Adanis: Energy Stocks Didn't Get The Memo Of Bears, Up 12% In 30-Days; 10 Stocks To BUY
For Daily Alerts
Cipla shares rally on anti-asthma inhaler launch in Germany
Shares in Cipla jumped sharply by 7 per cent after the pharma major launched an anti-asthma inhaler in Germany and Sweden. the stock was last trading at Rs 564 on the Bombay Stock Exchange.
The inhaler is a generic version of GlaxoSmithKline Plc's Advair.
Noted broking firm, Emkay Global upgraded the stock to "buy" from "accumulate" with a target of 671 rupees.
Overall addressable opportunity of generic Advair is $800 million in Europe, Emkay said.
Cipla shares were trading up 7.1 percent to 566.75 rupees as of 10:02 a.m.
GoodReturns.in
Story first published: Tuesday, September 2, 2014, 11:05 [IST]
More From GoodReturns
